

ASX release

3 October 2023

Change of Director's Interest – David Koczkar

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for David Koczkar for release to the market.

This document has been authorised for release by Mei Ramsay, Company Secretary.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: MEDIBANK PRIVATE LIMITED	
ABN: 47 080 890 259	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Koczkar
Date of last notice	6 September 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest Nature of indirect interest	Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan (<i>Performance Rights Plan</i>)
(including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	26 September 2023
No. of securities held prior to change	 1,688,255 Performance Rights, being: 718,849 Performance Rights granted under the FY22 Long Term Incentive (<i>LTI</i>); 240,566 Performance Rights granted under the FY22 Deferred Short Term Incentive (<i>Deferred STI</i>); and 728,840 Performance Rights granted under the FY23 LTI.
Class	Performance Rights
Number acquired	Nil

⁺ See chapter 19 for defined terms.

Number disposed	240,566 Performance Rights vested and converted to ordinary shares in Medibank Private Limited (<i>Ordinary Shares</i>) as set out below.
Value/Consideration	Performance Rights are granted at nil
Note: If consideration is non-cash, provide details and estimated	consideration under the terms of the
valuation	Performance Rights Plan.
No. of securities held after change	 1,447,689 Performance Rights, being: 718,849 Performance Rights granted under the FY22 LTI; and 728,840 Performance Rights granted under the FY23 LTI.
Nature of change	Vesting and exercise of Performance Rights
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	under the Performance Rights Plan

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest in Ordinary Shares held via Olive Man Investments Pty Ltd
Date of change	26 September 2023
No. of securities held prior to change	 1,171,323 Ordinary Shares, being: 312,589 Ordinary Shares (direct); and 858,734 Ordinary Shares (indirect).
Class	Ordinary Shares
Number acquired	 255,441 Ordinary Shares (direct), being: 240,566 Ordinary Shares following vesting of 240,566 Performance Rights granted under the FY22 Deferred STI; and 14,875 Ordinary Shares, being the number of Ordinary Shares having an equivalent value to the dividends that would have been received during the deferral period if Ordinary Shares were held instead of the
	Performance Rights granted under the FY22 Deferred STI.
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquisition of Ordinary Shares pursuant to vesting and exercise of Performance Rights under the Performance Rights Plan for no consideration.

⁺ See chapter 19 for defined terms.

No. of securities held after change	 1,426,764 Ordinary Shares, being: 568,030 Ordinary Shares (direct); and 858,734 Ordinary Shares (indirect).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Acquisition of Ordinary Shares pursuant to vesting and exercise of Performance Rights under the Performance Rights Plan.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.